Phase I/II Intratumoral DC Immunotherapy With Gemcitabine & XRT in Unresectable Pancreatic Cancer

Completed · Phase 1

Conditions studied: Pancreatic Cancer

In brief

To determine the safety, feasibility and appropriate dendritic cell dose to vaccinate patients with pancreas cancer

Key facts

Study ID

NCT00547144

Run by

George Albert Fisher

People needed

2

Starts

2005-10-01

Expected to finish

2008-04-01

Last updated by the study team

2012-11-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Stanford University School of Medicine — Stanford, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.